TY - JOUR
T1 - Advancing the global public health agenda for NAFLD
T2 - a consensus statement
AU - NAFLD Consensus Consortium
AU - Lazarus, Jeffrey V
AU - Mark, Henry E
AU - Anstee, Quentin M
AU - Arab, Juan Pablo
AU - Batterham, Rachel L
AU - Castera, Laurent
AU - Cortez-Pinto, Helena
AU - Crespo, Javier
AU - Cusi, Kenneth
AU - Dirac, M Ashworth
AU - Francque, Sven
AU - George, Jacob
AU - Hagström, Hannes
AU - Huang, Terry T-K
AU - Ismail, Mona H
AU - Kautz, Achim
AU - Sarin, Shiv Kumar
AU - Loomba, Rohit
AU - Miller, Veronica
AU - Newsome, Philip N
AU - Ninburg, Michael
AU - Ocama, Ponsiano
AU - Ratziu, Vlad
AU - Rinella, Mary
AU - Romero, Diana
AU - Romero-Gómez, Manuel
AU - Schattenberg, Jörn M
AU - Tsochatzis, Emmanuel A
AU - Valenti, Luca
AU - Wong, Vincent Wai-Sun
AU - Yilmaz, Yusuf
AU - Younossi, Zobair M
AU - Zelber-Sagi, Shira
N1 - © 2021. Springer Nature Limited.
PY - 2022/1
Y1 - 2022/1
N2 - Non-alcoholic fatty liver disease (NAFLD) is a potentially serious liver disease that affects approximately one-quarter of the global adult population, causing a substantial burden of ill health with wide-ranging social and economic implications. It is a multisystem disease and is considered the hepatic component of metabolic syndrome. Unlike other highly prevalent conditions, NAFLD has received little attention from the global public health community. Health system and public health responses to NAFLD have been weak and fragmented, and, despite its pervasiveness, NAFLD is largely unknown outside hepatology and gastroenterology. There is only a nascent global public health movement addressing NAFLD, and the disease is absent from nearly all national and international strategies and policies for non-communicable diseases, including obesity. In this global Delphi study, a multidisciplinary group of experts developed consensus statements and recommendations, which a larger group of collaborators reviewed over three rounds until consensus was achieved. The resulting consensus statements and recommendations address a broad range of topics - from epidemiology, awareness, care and treatment to public health policies and leadership - that have general relevance for policy-makers, health-care practitioners, civil society groups, research institutions and affected populations. These recommendations should provide a strong foundation for a comprehensive public health response to NAFLD.
AB - Non-alcoholic fatty liver disease (NAFLD) is a potentially serious liver disease that affects approximately one-quarter of the global adult population, causing a substantial burden of ill health with wide-ranging social and economic implications. It is a multisystem disease and is considered the hepatic component of metabolic syndrome. Unlike other highly prevalent conditions, NAFLD has received little attention from the global public health community. Health system and public health responses to NAFLD have been weak and fragmented, and, despite its pervasiveness, NAFLD is largely unknown outside hepatology and gastroenterology. There is only a nascent global public health movement addressing NAFLD, and the disease is absent from nearly all national and international strategies and policies for non-communicable diseases, including obesity. In this global Delphi study, a multidisciplinary group of experts developed consensus statements and recommendations, which a larger group of collaborators reviewed over three rounds until consensus was achieved. The resulting consensus statements and recommendations address a broad range of topics - from epidemiology, awareness, care and treatment to public health policies and leadership - that have general relevance for policy-makers, health-care practitioners, civil society groups, research institutions and affected populations. These recommendations should provide a strong foundation for a comprehensive public health response to NAFLD.
KW - Humans
KW - Non-alcoholic Fatty Liver Disease/diagnosis
UR - http://europepmc.org/abstract/med/34707258
U2 - 10.1038/s41575-021-00523-4
DO - 10.1038/s41575-021-00523-4
M3 - Review article
C2 - 34707258
SN - 1759-5045
VL - 19
SP - 60
EP - 78
JO - Nature Reviews. Gastroenterology & Hepatology
JF - Nature Reviews. Gastroenterology & Hepatology
IS - 1
ER -